James F. Callahan

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

Gareth J. Inman, Francisco José Nicolás, James F. Callahan et al. · Molecular Pharmacology · 2002 · 1.7K citations

Life Sciences, Molecular Biology, Pharmacology +13

Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur et al. · Molecular Pharmacology · 2002 · 650 citations

Life Sciences, Molecular Biology, Pharmacology +16

Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)

James F. Callahan, Joelle L. Burgess, James A. Fornwald et al. · Journal of Medicinal Chemistry · 2002 · 309 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery

Thomas G. Davies, William E. Wixted, Joseph E. Coyle et al. · Journal of Medicinal Chemistry · 2016 · 306 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

Patricia L. Podolin, James F. Callahan, Brian Bolognese et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 299 citations

Medicine, Immunology, Pharmacology +17